Gilead Sciences vs its peers
The 10 largest Biotechnology companies by market value, prices of Nov 20, 2026
Gilead Sciences is the 2nd largest of the 10 biggest Biotechnology companies on OQRO by market value, at $206B. Its revenue of $29.4B in fiscal 2025 ranks 2nd of 10. It keeps 34% of revenue as operating profit, 4th of 9 (median 29%). Revenue grew 2% on the year before, against a median of +8.0%. At 24.3x its latest annual earnings, the market prices it close to its peers (median 24.8x).
Side by side
| Company | Market value | Revenue | Growth y/y | 5-yr growth / yr | Gross margin | Operating margin | Net margin | Free cash flow margin | R&D / revenue | Price / earnings | Price / sales | FCF yield | Stock, 12 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AmgenAMGN · FY2025 | $236B | $36.8B | +10.0% | +7.6% | 67.2% | 24.7% | 21.0% | 22.0% | 19.8% | 30.6x | 6.4x | 3.4% |
Each company’s latest fiscal year (FY), so the years can end a few months apart. Price ratios divide today’s market value by that year’s figure; price / earnings is left out on a loss. “—” means the company did not tag that line in its annual report.
Operating margin
- UTHR47%
- EXEL38%
- VRTX35%
- GILD34%
- INCY29%
- REGN25%
- AMGN25%
- NBIX22%
- MRNA−158%
Compare Gilead Sciences head to head
Where Gilead Sciences’s revenue comes from and where it goes: Gilead Sciences revenue breakdown. Twenty years of results: Gilead Sciences financial history.
Common questions
Who are Gilead Sciences's competitors?
The largest companies in its industry (Biotechnology) by market value: Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Moderna (MRNA), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL) and Neurocrine Biosciences (NBIX). They share Gilead Sciences's industry listing; not every one competes with it on every product.
Is Gilead Sciences bigger than Amgen?
No, by market value: Gilead Sciences is worth $206B and Amgen $236B. By revenue, Gilead Sciences brought in $29.4B in fiscal 2025 and Amgen $36.8B in fiscal 2025.
How does Gilead Sciences's valuation compare with its peers?
Where these figures come from
The group is the companies OQRO lists in the same industry as Gilead Sciences (Biotechnology), the largest 9 by market value, plus Gilead Sciences. Companies whose latest annual report is more than a year and a half old, or that report in a currency other than the dollar, are left out.
Revenue, operating income, net income, gross profit, research and development and free cash flow (cash from operations minus capital expenditure) are each company’s own full-year lines from its latest 10-K, as tagged in XBRL (SEC companyfacts). Market value is the last close times the shares outstanding on the latest filing. Price / earnings is market value over net income; price / sales is market value over revenue; free cash flow yield is free cash flow over market value. Five-year growth is the yearly rate that takes revenue from five fiscal years before to the latest. This page describes the past and is not investment advice. No language model wrote it.









